Ascentage Pharma Group International (AAPG) Common Equity (2022 - 2025)

Ascentage Pharma Group International (AAPG) has disclosed Common Equity for 4 consecutive years, with $188.1 million as the latest value for Q4 2025.

  • For Q4 2025, Common Equity rose 411.46% year-over-year to $188.1 million; the TTM value through Dec 2025 reached $188.1 million, up 411.46%, while the annual FY2025 figure was $190.8 million, 657796.55% up from the prior year.
  • Common Equity hit $188.1 million in Q4 2025 for Ascentage Pharma Group International, up from $36.8 million in the prior quarter.
  • Across five years, Common Equity topped out at $188.1 million in Q4 2025 and bottomed at $9.8 million in Q4 2023.
  • Average Common Equity over 4 years is $73.0 million, with a median of $47.1 million recorded in 2022.
  • Year-over-year, Common Equity tumbled 82.93% in 2023 and then skyrocketed 411.46% in 2025.
  • Ascentage Pharma Group International's Common Equity stood at $57.5 million in 2022, then crashed by 82.93% to $9.8 million in 2023, then skyrocketed by 274.93% to $36.8 million in 2024, then surged by 411.46% to $188.1 million in 2025.
  • According to Business Quant data, Common Equity over the past three periods came in at $188.1 million, $36.8 million, and $9.8 million for Q4 2025, Q4 2024, and Q4 2023 respectively.